News

Video

Community Is ‘One of the Biggest Assets’ for Patients With MPNs

Author(s):

An expert explained the benefits of patients with myeloproliferative neoplasms finding a community of people with similar diagnoses.

Patients with myeloproliferative neoplasms (MPNs) can find immense benefit from joining a community of people with a similar diagnosis, according to Nichole Ard, senior clinical studies coordinator at The University of Texas MD Anderson Cancer Center in Houston.

MPNs are a group of rare blood disorders that affect the way that the bone marrow makes blood. MPN groups help patients connect, review resources and become more educated on their disease, according to Ard, who was also honored at CURE®’s 11th annual MPN Heroes® recognition event.

READ MORE:LeVar Burton Gives ‘Voice and Visibility’ to Patients with MPNs Through Storytelling and Advocacy

“I have patients that come in and they already know what I'm going to say half the time because they've talked to somebody else who's told them their story,” Ard said in an interview with CURE® ahead of the event.

Transcript

With my work, I've found that MPN patients find a community. There is a large community of patients that have gotten together, and they talk, and they review resources, and they tell their stories to each other, and I feel like that is probably one of the biggest assets for that community is that they are able to do those things.

I have patients that come in and they already know what I'm going to say half the time because they've talked to somebody else who's told them their story. And so I think that's a big part of any cancer is finding community, finding somebody who can relate with you in, in what you're going through. And I've, I've just found that that's been super helpful for my patients.


For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of Dr. Fakih.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Related Content